NCT05110196 2025-12-03Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.NovartisPhase 4 Completed50 enrolled
NCT02414139 2024-03-20Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)NovartisPhase 2 Completed373 enrolled 34 charts 3 FDA
NCT01610336 2021-04-08A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentNovartisPhase 2 Completed161 enrolled 32 charts